Eli Lilly (LLY): Revenue Boost From Zepbound and Mounjaro Amid Strong Market Projections
Express News | 'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
Behind the Scenes of Eli Lilly's Latest Options Trends
Investigating Eli Lilly's Standing In Pharmaceuticals Industry Compared To Competitors
OAC and Eli Lilly and Company Partner to Launch Bias-Free Obesity Image Gallery at HLTH 2024
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $990
Eli Lilly Price Target Announced at $1100.00/Share by Bernstein
Eli Lilly Analyst Ratings
$1000 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today
Investors in Eli Lilly (NYSE:LLY) Have Seen Fantastic Returns of 814% Over the Past Five Years
Eli Lilly Initiated With an Outperform at Bernstein
Bernstein starts to focus on US pharmaceutical stocks, giving Eli Lilly and Co (LLY.US) and others a "outperforming the large cap" rating.
Bernstein starts covering Eli Lilly and Co (LLY.US), Gilead Sciences (GILD.US), and Amgen (AMGN.US), all with an "outperform" rating.
Trump-Harris Race: Georgia Judge Overrules Republican-Enforced Election Rules Ahead Of Crucial November Elections: 'No Constitutional Authority To Promulgate'
Lilly, Gilead, Amgen Started at Outperform by Bernstein
Least Shorted S&P 500 Stocks in September
Lilly Confirms Date and Conference Call for Third-quarter 2024 Financial Results Announcement
Express News | Sunbird Bio: Raises $14 Mln, Backed by Eli Lilly and Strategic Investment Arm of Singapore Economic Development Board, Edbi
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Survey Reveals 8 in 10 Americans With Ulcerative Colitis Struggle to Find a Public Restroom During Emergencies